Advertisement

Liver-Directed Therapies in Neuroendocrine Tumors

  • Magaly ZappaEmail author
  • Annie Sibert
  • Mohamed Abdel-Rehim
  • Olivia Hentic
  • Maxime Ronot
  • Marie-Pierre Vullierme
  • Valérie Vilgrain
  • Philippe Ruszniewski

Abstract

Presence of liver metastases in neuroendocrine tumors is a major factor altering both quality of life and prognosis. Surgery is recognized as the sole curative treatment. When it is not possible, radiological-directed therapies are crucial.

This chapter addresses the various roles, technical issues, clinical efficacy, and safety of thermal ablation (radiofrequency, microwave, and cryotherapy) and transarterial embolization (bland embolization, chemoembolization, and radioembolization) as liver-directed therapies.

The choice of management depends on liver burden and metastases pattern but also on origin of the primary tumor, tumor differentiation, and tumor proliferative activity.

The treatment of neuroendocrine liver metastases still needs to be standardized. Management in centers of expertise should be strongly encouraged in order to enable a multidisciplinary approach to limit morbidity and mortality.

Keywords

Liver Metastasis Neuroendocrine Tumor Hormonal Symptom Bilioenteric Anastomosis Small Intestinal Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plockinger U (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12(6):361–379. doi: 10.1111/j.1477-2574.2010.00175.x, HPB175 [pii]CrossRefGoogle Scholar
  2. 2.
    Godwin JD 2nd (1975) Carcinoid tumors. An analysis of 2,837 cases. Cancer 36(2):560–569CrossRefPubMedGoogle Scholar
  3. 3.
    McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81(7):1007–1009CrossRefPubMedGoogle Scholar
  4. 4.
    Zeitels J, Naunheim K, Kaplan EL, Straus F 2nd (1982) Carcinoid tumors: a 37-year experience. Arch Surg 117(5):732–737CrossRefPubMedGoogle Scholar
  5. 5.
    Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60(7):1009–1021. doi: 10.1136/gut.2009.204453, gut.2009.204453 [pii]CrossRefPubMedGoogle Scholar
  6. 6.
    Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Levy P, Vilgrain V, Ruszniewski P, Belghiti J (2008) Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247(4):659–665. doi: 10.1097/SLA.0b013e31816a7061 CrossRefPubMedGoogle Scholar
  7. 7.
    Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C, Baudin E (2003) Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133(4):375–382. doi: 10.1067/msy.2003.114, S0039606003000096 [pii]CrossRefPubMedGoogle Scholar
  8. 8.
    Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445, doi:S1072-7515(00)00222-2 [pii]CrossRefPubMedGoogle Scholar
  9. 9.
    Elias D, Goere D, Leroux G, Dromain C, Leboulleux S, de Baere T, Ducreux M, Baudin E (2009) Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 35(10):1092–1097. doi: 10.1016/j.ejso.2009.02.017, S0748-7983(09)00077-8 [pii]CrossRefPubMedGoogle Scholar
  10. 10.
    Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E (2010) Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 148(6):1288–1293. doi: 10.1016/j.surg.2010.09.014; discussion 1293. S0039-6060(10)00506-4 [pii]CrossRefPubMedGoogle Scholar
  11. 11.
    Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242(2):158–171, doi:00000658-200508000-00003 [pii]CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Berber E, Siperstein AE (2007) Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc 21(4):613–618. doi: 10.1007/s00464-006-9139-y CrossRefPubMedGoogle Scholar
  13. 13.
    Mazzaglia PJ, Berber E, Milas M, Siperstein AE (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142(1):10–19. doi: 10.1016/j.surg.2007.01.036, S0039-6060(07)00201-2 [pii]CrossRefPubMedGoogle Scholar
  14. 14.
    Martin RC, Scoggins CR, McMasters KM (2010) Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 17(1):171–178. doi: 10.1245/s10434-009-0686-z CrossRefPubMedGoogle Scholar
  15. 15.
    Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP (1997) Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122(6):1040–1047; discussion 1047–1048. doi:S0039-6060(97)90207-5 [pii]CrossRefPubMedGoogle Scholar
  16. 16.
    Seifert JK, Cozzi PJ, Morris DL (1998) Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14(2):175–183, doi:10.1002/(SICI)1098-2388(199803)14:2<175::AID-SSU10>3.0.CO;2-2 [pii]CrossRefPubMedGoogle Scholar
  17. 17.
    Shapiro RS, Shafir M, Sung M, Warner R, Glajchen N (1998) Cryotherapy of metastatic carcinoid tumors. Abdom Imaging 23(3):314–317CrossRefPubMedGoogle Scholar
  18. 18.
    Steward MJ, Warbey VS, Malhotra A, Caplin ME, Buscombe JR, Yu D (2008) Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics 28(4):1131–1145. doi: 10.1148/rg.284075170, 28/4/1131 [pii]CrossRefPubMedGoogle Scholar
  19. 19.
    Granberg D, Eriksson LG, Welin S, Kindmark H, Janson ET, Skogseid B, Oberg K, Eriksson B, Nyman R (2007) Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors. Acta Radiol 48(2):180–185. doi: 10.1080/02841850601080440, 772611718 [pii]CrossRefPubMedGoogle Scholar
  20. 20.
    Therasse E, Breittmayer F, Roche A, De Baere T, Indushekar S, Ducreux M, Lasser P, Elias D, Rougier P (1993) Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 189(2):541–547CrossRefPubMedGoogle Scholar
  21. 21.
    Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S (1986) The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147(1):149–154CrossRefPubMedGoogle Scholar
  22. 22.
    Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors–a retrospective single-center analysis. Digestion 68(2–3):94–101. doi: 10.1159/000074522, 74522 [pii]CrossRefPubMedGoogle Scholar
  23. 23.
    Eriksson BK, Larsson EG, Skogseid BM et al (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83(11):2293–2301, doi:10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E [pii]CrossRefPubMedGoogle Scholar
  24. 24.
    Kim YH, Ajani JA, Carrasco CH et al (1999) Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 17(7):474–478CrossRefPubMedGoogle Scholar
  25. 25.
    Marrache F, Vullierme MP, Roy C et al (2007) Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 96(1):49–55. doi: 10.1038/sj.bjc.6603526, 6603526 [pii]CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Roche A, Girish BV, de Baere T et al (2004) Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 51(60):1751–1756PubMedGoogle Scholar
  27. 27.
    Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590–1602. doi: 10.1002/cncr.21389 CrossRefPubMedGoogle Scholar
  28. 28.
    Ruszniewski P, Rougier P, Roche A et al (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71(8):2624–2630CrossRefPubMedGoogle Scholar
  29. 29.
    Maire F, Lombard-Bohas C, O’Toole D et al (2012) Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases of well-differentiated midgut endocrine tumors. A prospective randomized study. Neuroendocrinology 96:294–300CrossRefPubMedGoogle Scholar
  30. 30.
    Pitt SC, Knuth J, Keily JM et al (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12(11):1951–1960. doi: 10.1007/s11605-008-0640-6 CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Ruutiainen AT, Soulen MC, Tuite CM et al (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18(7):847–855. doi: 10.1016/j.jvir.2007.04.018, 18/7/847 [pii]CrossRefPubMedGoogle Scholar
  32. 32.
    Fiore F, Del Prete M, Franco R et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47:177–182. doi: 10.1007/s12020-013-0130-9 CrossRefPubMedGoogle Scholar
  33. 33.
    Strosberg JR, Weber JM, Choi J et al (2012) A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 23(9):2335–2341. doi: 10.1093/annonc/mdr614, mdr614 [pii]CrossRefPubMedGoogle Scholar
  34. 34.
    Dominguez S, Denys A, Madeira I et al (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12(2):151–157CrossRefPubMedGoogle Scholar
  35. 35.
    Ho AS, Picus J, Darcy MD et al (2007) Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188(5):1201–1207. doi: 10.2214/AJR.06.0933, 188/5/1201 [pii]CrossRefPubMedGoogle Scholar
  36. 36.
    Strosberg JR, Choi J, Cantor AB, Kvols LK (2006) Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13(1):72–78PubMedGoogle Scholar
  37. 37.
    Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52. doi: 10.1007/s00270-009-9711-7 CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, Leboulleux S, Baudin E, Hechellhammer L (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19(6):855–861. doi: 10.1016/j.jvir.2008.01.030, S1051-0443(08)00183-8 [pii]CrossRefPubMedGoogle Scholar
  39. 39.
    Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, Kulke M, Baum R (2011) Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 34(3):566–572. doi: 10.1007/s00270-011-0122-1 CrossRefPubMedGoogle Scholar
  40. 40.
    Guiu B, Deschamps F, Aho S et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56(3):609–617. doi: 10.1016/j.jhep.2011.09.012, S0168-8278(11)00773-2 [pii]CrossRefPubMedGoogle Scholar
  41. 41.
    Bhagat N, Reyes DK, Lin M et al (2013) Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 36(2):449–459. doi: 10.1007/s00270-012-0424-y CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A (2012) Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 17(5):725–731. doi: 10.1634/theoncologist.2011-0372, theoncologist.2011-0372 [pii]CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Hoffmann RT, Paprottka P, Jakobs TF, Trumm CG, Reiser MF (2011) Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Abdom Imaging 36(6):671–676. doi: 10.1007/s00261-011-9753-6 CrossRefPubMedGoogle Scholar
  44. 44.
    Varker KA, Martin EW, Klemanski D, Palmer B, Shah MH, Bloomston M (2007) Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE. J Gastrointest Surg 11(12):1680–1685. doi: 10.1007/s11605-007-0235-7 CrossRefPubMedGoogle Scholar
  45. 45.
    Kim W, Clark TW, Baum RA, Soulen MC (2001) Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12(8):965–968CrossRefPubMedGoogle Scholar
  46. 46.
    de Baere T, Roche A, Amenabar JM, Lagrange C, Ducreux M, Rougier P, Elias D, Lasser P, Patriarche C (1996) Liver abscess formation after local treatment of liver tumors. Hepatology 23(6):1436–1440. doi: 10.1002/hep.510230620, S0270913996002315 [pii]CrossRefPubMedGoogle Scholar
  47. 47.
    Woo S, Chung JW, Hur S, Joo SM, Kim HC, Jae HJ, Park JH (2013) Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol 200(6):1370–1377. doi: 10.2214/AJR.12.9630 CrossRefPubMedGoogle Scholar
  48. 48.
    Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH (1999) Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10(4):397–403CrossRefPubMedGoogle Scholar
  49. 49.
    Sommer WH, Ceelen F, Garcia-Albeniz X et al (2013) Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol 23(11):3094–3103. doi: 10.1007/s00330-013-2925-8 CrossRefPubMedGoogle Scholar
  50. 50.
    Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31(3):271–279. doi: 10.1097/COC.0b013e31815e4557, 00000421-200806000-00012 [pii]CrossRefPubMedGoogle Scholar
  51. 51.
    Cao CQ, Yan TD, Bester L, Liauw W, Morris DL (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97(4):537–543. doi: 10.1002/bjs.6931 CrossRefPubMedGoogle Scholar
  52. 52.
    Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H, Gress TM, Arnold R, Klose KJ, Wagner HJ (2009) Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79(3):137–142. doi: 10.1159/000209849, 000209849 [pii]CrossRefPubMedGoogle Scholar
  53. 53.
    King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113(5):921–929. doi: 10.1002/cncr.23685 CrossRefPubMedGoogle Scholar
  54. 54.
    Paprottka PM, Hoffmann RT, Haug A et al (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35(2):334–342. doi: 10.1007/s00270-011-0248-1 CrossRefPubMedGoogle Scholar
  55. 55.
    Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, Benson AB 3rd, Kennedy AS, Omary RA, Salem R (2008) 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247(6):1029–1035. doi: 10.1097/SLA.0b013e3181728a45, 00000658-200806000-00017 [pii]CrossRefPubMedGoogle Scholar
  56. 56.
    Saxena A, Chua TC, Bester L, Kokandi A, Morris DL (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251(5):910–916. doi: 10.1097/SLA.0b013e3181d3d24a CrossRefPubMedGoogle Scholar
  57. 57.
    Ceelen F, Theisen D, de Albeniz XG et al (2014) Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? J Magn Reson Imaging. doi: 10.1002/jmri.24569
  58. 58.
    Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Gates VL, Atassi B, Newman S, Omary RA, Benson AB 3rd, Salem R (2012) Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 83(3):887–894. doi: 10.1016/j.ijrobp.2011.07.041, S0360-3016(11)03133-6 [pii]CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Rajekar H, Bogammana K, Stubbs RS (2011) Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int J Hepatol 2011:404916. doi: 10.4061/2011/404916 PubMedCentralPubMedGoogle Scholar
  60. 60.
    Benson AB 3rd, Geschwind JF, Mulcahy MF et al (2013) Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 49(15):3122–3130. doi: 10.1016/j.ejca.2013.05.012, S0959-8049(13)00409-7 [pii]CrossRefPubMedGoogle Scholar
  61. 61.
    Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O’Dorisio TM, Howe J, Button A, Zamba G, Halfdanarson TR (2014) Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas 43(2):219–225. doi: 10.1097/MPA.0000000000000030, 00006676-201403000-00007 [pii]CrossRefPubMedCentralPubMedGoogle Scholar
  62. 62.
    Whitney R, Valek V, Fages JF, Garcia A, Narayanan G, Tatum C, Hahl M, Martin RC 2nd (2011) Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist 16(5):594–601. doi: 10.1634/theoncologist.2010-0292, theoncologist.2010-0292 [pii]CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Yang TX, Chua TC, Morris DL (2012) Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – a systematic review. Surg Oncol 21(4):299–308. doi: 10.1016/j.suronc.2012.07.001, S0960-7404(12)00054-0 [pii]CrossRefPubMedGoogle Scholar
  64. 64.
    Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176. doi: 10.1159/000335597, 000335597 [pii]CrossRefPubMedGoogle Scholar
  65. 65.
    Cadiot G (2010) Tumeurs endocrines digestives. Thésaurus National de cancérologie Digestive. Available via http://www.snfge.org/data/moduledocument/publication/5/1252.htm

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Magaly Zappa
    • 1
    • 2
    Email author
  • Annie Sibert
    • 1
  • Mohamed Abdel-Rehim
    • 1
  • Olivia Hentic
    • 3
  • Maxime Ronot
    • 1
    • 2
  • Marie-Pierre Vullierme
    • 1
  • Valérie Vilgrain
    • 1
    • 2
  • Philippe Ruszniewski
    • 3
    • 2
  1. 1.Department of RadiologyHôpital Beaujon, Assistance Publique-Hôpitaux de ParisClichyFrance
  2. 2.Univ Paris Diderot, SorbonneParisFrance
  3. 3.Department of GastroenterologyHôpital Beaujon, Assistance Publique-Hôpitaux de ParisClichyFrance

Personalised recommendations